secwatch.observer — SEC 8-K summary
======================================

Issuer:     KalVista Pharmaceuticals, Inc. (KALV)
CIK:        0001348911
Form:       8-K
Filed at:   2022-10-17T23:59:59+00:00
Accession:  0000950170-22-019610
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 5.07, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

KalVista Pharmaceuticals appoints Brian J.G. Pereira as Chairman; Martin Edwards resigns in planned transition
--------------------------------------------------------------------------------

- Martin Edwards resigned as Chairman and director effective immediately; departure not due to any disagreement.
- Brian J.G. Pereira appointed Chairman; previously a board member since 2019 and President & CEO of Visterra.
- Annual meeting results: T. Andrew Crockett and Brian J.G. Pereira elected as Class I directors.
- Deloitte & Touche ratified as auditor for FY ending April 30, 2023; advisory say-on-pay approved.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1348911/000095017022019610/0000950170-22-019610-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1348911/000095017022019610/kalv-20221013.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-019610

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer